Adaptive Biotechnologies Corporation $ADPT Shares Bought by Algert Global LLC

Algert Global LLC raised its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 215.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 522,020 shares of the company’s stock after buying an additional 356,677 shares during the quarter. Algert Global LLC owned about 0.34% of Adaptive Biotechnologies worth $7,809,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ADPT. XTX Topco Ltd acquired a new position in Adaptive Biotechnologies during the 2nd quarter valued at approximately $793,000. SG Americas Securities LLC raised its holdings in shares of Adaptive Biotechnologies by 53.2% in the second quarter. SG Americas Securities LLC now owns 37,328 shares of the company’s stock worth $435,000 after buying an additional 12,963 shares during the last quarter. Allianz Asset Management GmbH lifted its stake in shares of Adaptive Biotechnologies by 305.8% during the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock worth $4,814,000 after buying an additional 242,474 shares during the period. Hillsdale Investment Management Inc. acquired a new stake in shares of Adaptive Biotechnologies during the second quarter worth $6,618,000. Finally, Envestnet Asset Management Inc. purchased a new stake in shares of Adaptive Biotechnologies during the second quarter valued at $467,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Wall Street Analyst Weigh In

ADPT has been the topic of several research reports. JPMorgan Chase & Co. upped their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Morgan Stanley began coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target on the stock. BTIG Research increased their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Finally, Guggenheim lifted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

Adaptive Biotechnologies Trading Up 1.1%

Shares of ADPT stock opened at $13.32 on Tuesday. Adaptive Biotechnologies Corporation has a twelve month low of $6.68 and a twelve month high of $20.76. The stock has a market cap of $2.05 billion, a P/E ratio of -33.30 and a beta of 2.19. The stock has a 50 day moving average of $16.50 and a 200 day moving average of $15.89.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.10. The business had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business’s quarterly revenue was up 51.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.23) EPS. On average, research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Julie Rubinstein sold 141,583 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.29, for a total transaction of $1,881,638.07. Following the sale, the chief operating officer directly owned 516,610 shares of the company’s stock, valued at $6,865,746.90. This represents a 21.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Sharon Benzeno sold 63,103 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $831,066.51. Following the completion of the sale, the insider directly owned 272,751 shares in the company, valued at approximately $3,592,130.67. The trade was a 18.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 2,350,698 shares of company stock valued at $34,449,277. Insiders own 6.40% of the company’s stock.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.